Gencurix Inc.
KOE: 229000.KQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Medical - Specialties
- CEO
- Sung-Rai Cho
- Employees
- 69
- Headquarters
- Seoul, South Korea
- IPO year
- 2017
- Market cap
- ₩59.2B
- Website
- https://www.gencurix.com
Loading 229000…
Loading profile data…Frequently asked questions about 229000
What does Gencurix Inc. (229000.KQ) do?
Gencurix Inc. provide diagnostic solutions in South Korea. Its products include GenesWell BCT, a prognosis diagnostic test for breast cancer; GenesWell ddEGFR Mutation Test, a companion test for lung cancer; Droplex, a genetic test that detects DNA mutations; eDX, an early diagnosis for cancer with liquid biopsy; GenePro COVID-19 detection test;...
Where does 229000.KQ trade?
Gencurix Inc. (229000.KQ) trades on the KOSDAQ.
What sector is 229000.KQ in?
Gencurix Inc. (229000.KQ) operates in the Healthcare sector, specifically in the Medical - Specialties industry.
Who is the CEO of Gencurix Inc.?
Sung-Rai Cho is the chief executive officer of Gencurix Inc. (229000.KQ).
Where is Gencurix Inc. headquartered?
Gencurix Inc. is headquartered in South Korea.
Does 229000.KQ pay a dividend?
Gencurix Inc. (229000.KQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 229000.KQ go public?
Gencurix Inc. (229000.KQ) completed its initial public offering in 2017.